TY - JOUR
T1 - Expression of Apoptosis Regulating Proteins Identifies Stage II and III Colon Cancer Patients With High Risk of Recurrence
AU - Belt, Eric
AU - Stockmann, HBAC
AU - Delis-van Diemen, PM
AU - Bril, H
AU - Tijssen, M
AU - Van Essen, HF
AU - Heymans, MW
AU - Belien, JAM
AU - Carvalho, B
AU - Cillessen, SAGM
AU - Meijer, GA
PY - 2014
Y1 - 2014
N2 - Background and ObjectivesDeregulation of apoptosis related genes may be associated with poor outcome in cancer. Aim of the present study was to investigate the prognostic role of expression levels of apoptosis related proteins in stage II and III colon cancer. MethodsFrom tumor samples of 386 stage II and III colon cancer patients, DNA was isolated and tissue microarrays were constructed. Expression of Bcl-2, Bcl-X, BAX, XIAP, Fas, FasL and c-FLIP was evaluated and PCR-based microsatellite instability analysis was performed. ResultsHigh FasL expressing tumors were associated with high disease recurrence rates in stage II colon cancer patients overall, as was low Bcl-X expression in microsatellite stable stage II patients. In stage II patients, a multivariable model based on FasL and Bcl-XL expression revealed a significant association with disease free survival (DFS). In stage III colon cancer patients, low Bcl-2, low BAX and low Fas expression levels were associated with worse outcome. In these patients a multivariable model based on angioinvasion and Bcl-2, Fas and FasL expression was significantly associated with DFS. ConclusionsStage II patients with low Bcl-X and high FasL protein expression levels and stage III patients with low Fas, high FasL and low Bcl-2 expression could be considered as high risk for disease recurrence. J. Surg. Oncol. 2014 109:255-265. (c) 2013 Wiley Periodicals, Inc.
AB - Background and ObjectivesDeregulation of apoptosis related genes may be associated with poor outcome in cancer. Aim of the present study was to investigate the prognostic role of expression levels of apoptosis related proteins in stage II and III colon cancer. MethodsFrom tumor samples of 386 stage II and III colon cancer patients, DNA was isolated and tissue microarrays were constructed. Expression of Bcl-2, Bcl-X, BAX, XIAP, Fas, FasL and c-FLIP was evaluated and PCR-based microsatellite instability analysis was performed. ResultsHigh FasL expressing tumors were associated with high disease recurrence rates in stage II colon cancer patients overall, as was low Bcl-X expression in microsatellite stable stage II patients. In stage II patients, a multivariable model based on FasL and Bcl-XL expression revealed a significant association with disease free survival (DFS). In stage III colon cancer patients, low Bcl-2, low BAX and low Fas expression levels were associated with worse outcome. In these patients a multivariable model based on angioinvasion and Bcl-2, Fas and FasL expression was significantly associated with DFS. ConclusionsStage II patients with low Bcl-X and high FasL protein expression levels and stage III patients with low Fas, high FasL and low Bcl-2 expression could be considered as high risk for disease recurrence. J. Surg. Oncol. 2014 109:255-265. (c) 2013 Wiley Periodicals, Inc.
U2 - 10.1002/jso.23495
DO - 10.1002/jso.23495
M3 - Article
C2 - 24249458
SN - 0022-4790
VL - 109
SP - 255
EP - 265
JO - Journal of Surgical Oncology
JF - Journal of Surgical Oncology
IS - 3
ER -